SGT 701
Alternative Names: AVB-601; SGT-701Latest Information Update: 30 Mar 2023
At a glance
- Originator Avanti Biosciences
- Developer Solid Biosciences
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; RNA-binding protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypertrophic cardiomyopathy
Highest Development Phases
- Preclinical Hypertrophic cardiomyopathy